Revolution Medicines Reports Positive Phase 3 Trial

Revolution Medicines shares jumped 33% after reporting positive Phase 3 RASolute 302 trial results in metastatic pancreatic cancer.
Daraxonrasib showed median overall survival of 13.2 months versus 6.7 months for chemotherapy, hazard ratio 0.40.
The trial met all primary (PFS, OS) and key secondary endpoints, enrolling patients with various RAS mutations and wild‑type tumors.
Revolution plans to file the data with global regulators, including the FDA, and present findings at the 2026 ASCO meeting.